Smith+Nephew's ESSA Spatial Surgery System Receives FDA's De Novo Classification
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been granted De Novo classification by the U.S. Food & Drug Administration (FDA) for its TESSA Spatial Surgery System.
Smith+Nephew got special FDA approval for a new surgical tool called TESSA, which means the tool is unique and the company can now sell it in the U.S. This shows the company is creating new things doctors might want to use.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.